Finny logo
Finny logo
Dibs:
Dibs:
0

Immune Pharmaceuticals (IMNP) earnings: hoping for good news?

6:24 pm ET, 20 Jun 2018

On Monday, June 25, before the opening bell Immune Pharmaceuticals Inc. (IMNP) is announcing its Q2'18 earnings.  Immune Pharmaceuticals shares are trading at 0.21, down -0.38% from yesterday.  What can you expect from IMNP earnings?  What is IMNP stock forecast?  

For the first quarter of FY18, the company is expected to produce an Earnings Per Share (EPS) of -$0.20.  The company did better than the analysts' expectation of -$0.15 by five cents.  

For the second quarter, the analysts are predicting an Earnings Per Share (EPS) of -$0.21.

Immune Pharmaceuticals ("Immune") is a biopharma developing new therapeutic agents for the treatment of immunologic and inflammatory diseases.  The company is focused on establishing a clear path forward for bertilimumab and NanoCyclo (two key programs) by implementing strategic corporate restructuring and prioritizing R&D efforts focused on those two initiatives. 

During 2017 the company began a spin-off of Cytovia into a separate, stand-alone company. Cytovia focuses on the development and commercialization of novel oncology and hematology therapeutics and is seeking separate capitalization from third-party sources for start-up costs, expenses of the spin-off and ongoing R&D efforts.  

Over the last month, Immune Pharmaceuticals Inc. (IMNP) returned -16.4%.

Immune Pharmaceuticals Inc. (IMNP) average analyst price target ($2.00) is 847.42% above its current price ($0.21).

For the latest price and information on Immune Pharmaceuticals Inc., please visit Finstead and search for "IMNP price" or "IMNP news".

Immune Pharmaceuticals Inc. (IMNP) Stock Guide

Updated at: 1:02 am ET, 22 Nov 2020

Before we start: if you're looking for IMNP stock price, you can quickly find it out by visiting Finny and typing "IMNP quote". If you're looking for a quick scoop on IMNP stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "IMNP". You'll get all this info in one place. Or you can just type "IMNP news" to get the latest stock news.

Looking to buy or sell Immune Pharmaceuticals Inc. (IMNP)? Interested in getting the full scoop on IMNP, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this IMNP stock guide, we'll address key questions about IMNP, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. IMNP buy or sell? What is IMNP Finny Score?
2. What are the reasons to buy IMNP? Why should I buy IMNP stock?
3. What are the reasons to sell IMNP? Why should I sell IMNP stock?
4. What are IMNP key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Analysis

1. IMNP buy or sell? What is IMNP Finny Score?

#{finnyScore:null}Our quantitative analysis shows 1 reason to buy and 0 reasons to sell IMNP. IMNP doesn’t have an assigned Finny Score, because we don’t have sufficient data points to score the stock.

2. What are the reasons to buy IMNP? Why should I buy IMNP stock?

Here are the reasons to buy IMNP stock:

  • IMNP stock price ($0.00) is close to the 52-week low ($0.00). Perhaps now is a good time to buy? See IMNP price chart.

3. What are the reasons to sell IMNP? Why should I sell IMNP stock?

We can’t think of any good reason to sell this stock, which doesn’t mean they don’t exist.

Key Stats

4. What are IMNP key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for IMNP:

Metrics IMNP
Price $0.16
Average Price Target / Upside N/A
Average Analyst Rating N/A
Forward Dividend Yield 0.00%
Industry Drug Manufacturers - Major
Sector Healthcare
Number of Employees N/A
Market Cap $00
Forward P/E Ratio N/A
Price/Book Ratio N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin N/A

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us